STORZ MEDICAL’s NEUROLITH® receives CE approval – Transcranial Pulse Stimulation (TPS) on the central nervous system of patients with Alzheimer’s disease


In December 2018, STORZ MEDICAL has received the CE approval for the NEUROLITH®, a new therapy system for the treatment of neurological diseases.

The technology behind the NEUROLITH® is called Transcranial Pulse Stimulation (TPS). TPS consists of short acoustic pulses with an ultrasound frequency range that permits a well-focused stimulation of the brain at a depth of up to 5 cm.
The pivotal study for the NEUROLITH® showed that TPS can not only maintain the cognitive abilities of patients with mild to moderate Alzheimer’s disease, but even improve them significantly. The data also showed that the improvements last for at least 3 months after the completion of the TPS treatment series. On average, cognition was improved by 10 points on the CERAD scale. This was also confirmed by patients and their relatives: in everyday life, they noticed improved verbal abilities and an improved memory, which indirectly led to an increase in social interaction. Some patients had an improved sense of direction that enabled them to do their shopping independently again and to go home afterwards.

Further information on the new NEUROLITH® will soon be available on the STORZ MEDICAL website.


Related Posts



No comments made yet. Be the first to submit a comment
Sunday, 26 June 2022
Linkedin Channel Facebook Channel Instagram Channel Twitter Youtube Channel